A Role for Virtual Biotechnology Companies in Drug Discovery and Development

摘要: The orthodox business model of many drug discovery and development companies centers on adding value to early-stage discoveries prior engaging with large pharmaceutical bring products market. Anecdotal observations suggest some are moving a 'virtual' — instead employing in-house scientists, skeletal management team runs the company out-sources all research development. This article presents novel method determine whether virtual, based author bylines in peer-reviewed journal articles.Applying this Australian sector, size cohort identified as virtual was much larger than anticipated, around 52%. accuracy has been verified statistically using interview data. discusses limitations method, positing that it can be used analyse industry policy implications may result from widespread adoption model.